Axsome Therapeutics Inc (AXSM)

Feb 22, 2025

10 Best Performing Pharma Stocks So Far in 2025 - Insider Monkey

Feb 22, 2025

Feb 22, 2025

Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat

Feb 22, 2025

Feb 22, 2025

Q1 Earnings Estimate for AXSM Issued By HC Wainwright - MarketBeat

Feb 22, 2025

Feb 22, 2025

William Blair Issues Negative Outlook for AXSM Earnings - MarketBeat

Feb 22, 2025

Feb 22, 2025

FY2025 EPS Estimate for Axsome Therapeutics Cut by Analyst - MarketBeat

Feb 22, 2025

Feb 22, 2025

Leerink Partnrs Brokers Increase Earnings Estimates for AXSM - MarketBeat

Feb 22, 2025

Feb 21, 2025

Axsome Therapeutics stock soars to all-time high of $134.2 By Investing.com - Investing.com Nigeria

Feb 21, 2025

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Feb 21, 2025

Axsome Therapeutics stock soars to all-time high of $134.2 - Investing.com India

Feb 21, 2025

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Feb 21, 2025

Astrazeneca, Vertex, Axsome secure US FDA approvals in January - BioWorld Online

Feb 21, 2025

Feb 21, 2025

Axsome Therapeutics targets multiple NDA submissions and pipeline advancements through 2025 - MSN

Feb 21, 2025

Feb 21, 2025

Mizuho maintains Axsome Outperform rating, $195 target - Investing.com

Feb 21, 2025

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $200.00 at HC Wainwright - MarketBeat

Feb 21, 2025

Feb 21, 2025

FY2028 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat

Feb 21, 2025

Feb 21, 2025

Axsome Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks

Feb 21, 2025

Feb 21, 2025

Strategic Financial Concepts LLC Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Feb 21, 2025

Feb 20, 2025

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - AOL

Feb 20, 2025

Feb 20, 2025

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN

Feb 20, 2025

Feb 20, 2025

Axsome Therapeutics (NASDAQ:AXSM) Receives Outperform Rating from William Blair - MarketBeat

Feb 20, 2025

Feb 20, 2025

Truist Financial Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Feb 20, 2025

Cantor Fitzgerald Reaffirms Overweight Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat

Feb 20, 2025

Feb 20, 2025

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering (NASDAQ:AXSM) - Seeking Alpha

Feb 20, 2025

Feb 20, 2025

Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Feb 20, 2025

Axsome Therapeutics Revenue Surges 66% - MSN

Feb 20, 2025

Feb 20, 2025

Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 - MSN

Feb 20, 2025

Feb 19, 2025

Axsome Therapeutics (NASDAQ:AXSM) Shares Gap DownTime to Sell? - MarketBeat

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey

Feb 19, 2025

Feb 19, 2025

William Blair Reiterates Outperform Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat

Feb 19, 2025

Feb 19, 2025

RBC Capital Adjusts Price Target on Axsome Therapeutics to $192 From $143, Keeps Outperform Rating - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics price target raised to $153 from $133 at Needham - TipRanks

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 19, 2025

Feb 19, 2025

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $200 From $176, Maintains Buy Rating - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics (NASDAQ:AXSM) Stock Quotes, Forecast and News Summary - Benzinga

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Peregrine Capital Management LLC - MarketBeat

Feb 19, 2025

Feb 19, 2025

Axsome: Q4 Earnings Snapshot - CT Insider

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics (AXSM) to Release Quarterly Earnings on Tuesday - MarketBeat

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics, Penumbra, Republic Services - TradingView

Feb 19, 2025

Feb 19, 2025

Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ... By GuruFocus - Investing.com Canada

Feb 19, 2025

Feb 18, 2025

Axsome Therapeutics Sees Robust Growth and Strategic Progress - TipRanks

Feb 18, 2025

Feb 18, 2025

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? - MSN

Feb 18, 2025

Feb 18, 2025

Axsome Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 18, 2025

Feb 18, 2025

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Feb 18, 2025

Feb 18, 2025

Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth - MSN

Feb 18, 2025

Feb 18, 2025

Truist Securities Raises Price Target on Axsome Therapeutics to $200 From $190, Keeps Buy Rating - Marketscreener.com

Feb 18, 2025

Feb 18, 2025

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst - Benzinga

Feb 18, 2025

Feb 18, 2025

Earnings call transcript: Axsome misses Q4 2024 forecasts, stock dips By Investing.com - Investing.com South Africa

Feb 18, 2025

Feb 18, 2025

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 18, 2025

Feb 18, 2025

Axsome Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 18, 2025

Feb 18, 2025

Earnings call transcript: Axsome misses Q4 2024 forecasts, stock dips - Investing.com

Feb 18, 2025